Lovaza and Simponi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lovaza (omega-3-acid ethyl esters) and Simponi (golimumab). Common drug interactions include body mass index increased among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Lovaza and Simponi. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Lovaza?

Lovaza has active ingredients of omega-3-acid ethyl esters. It is often used in high blood cholesterol. eHealthMe is studying from 17,340 Lovaza users. Check the latest studies of Lovaza.

What is Simponi?

Simponi has active ingredients of golimumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 86,328 Simponi users. Check the latest studies of Simponi.

On Jul, 12, 2026

24 people who take Lovaza and Simponi together, and have interactions are studied.

What are the common drug interactions of Lovaza and Simponi, by gender? *:

female:

Body mass index increased
Hypoaesthesia (reduced sense of touch or sensation)
Rash
Procedural pain
Bedridden
Drug ineffective
Fatigue (feeling of tiredness)
Gait disturbance
Muscular weakness (muscle weakness)
Myalgia (muscle pain)

male:

Drug ineffective
Infection
Bradycardia neonatal (sinus rhythm with a heart rate below the normal limit in newborn)
Continuous positive airway pressure
Dyspnoea (difficult or laboured respiration)
Fall
Fatigue (feeling of tiredness)
Foetal exposure during pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect)
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
Heart rate decreased

What are the common drug interactions of Lovaza and Simponi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Kidney infection
Therapeutic response decreased (less preventive response)
Drug ineffective

50-59:

Body mass index increased
Hypoaesthesia (reduced sense of touch or sensation)
Procedural pain
Bedridden
Gait disturbance
Muscular weakness (muscle weakness)
Myalgia (muscle pain)
Neuropathy peripheral (surface nerve damage)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)

60+:

Drug ineffective
Infection
Back disorder
Dry mouth
Dyspnoea (difficult or laboured respiration)
Fall
Haematochezia (passage of stools containing blood)
Hidradenitis (chronic disease of a type of sweat gland)
Intestinal haemorrhage (bleeding from intestine)
Nasopharyngitis (inflammation of the nasopharynx)

What are the existing conditions these people have? *

Pain: 9 people, 37.50%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 6 people, 25.00%
Radiculopathy (a set of conditions in which one or more nerves is affected and does not work properly): 6 people, 25.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 25.00%
Stress And Anxiety: 5 people, 20.83%
Nausea (feeling of having an urge to vomit): 4 people, 16.67%
Back Pain: 4 people, 16.67%
Headache (pain in head): 4 people, 16.67%
Itching: 4 people, 16.67%
Migraine (headache): 4 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Lovaza and Simponi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously